BNP Paribas Exane initiated coverage of AstraZeneca (AZN) with an Outperform rating and $75 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Pfizer Stock (PFE) Dips after Weight-Loss Pill Halted Over Liver Injury
- Novartis Stock (NVS) Looks Healthier as it Spends $23B on Ramping Up U.S. Manufacturing
- Trump plans to announce ‘major’ tariff on pharmaceutical imports, Reuters says
- Trump Plans “Major Tariff on Pharmaceuticals” as Global Economies Crumble
- AstraZeneca’s Oncology Breakthroughs: Buy Rating Backed by Promising Pipeline and Strategic Innovations